YM Biosciences was founded in 1994 and is headquartered in Mississauga, Canada. YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, is used for the treatment nasopharyngeal carcinomas, head and neck cancer, refractory children glioma, adult glioma, and stage III/IV glioma. The company is also developing Nimotuzumab for various other epithelial cancers; and AeroLEF, a proprietary formulation of free and liposome-encapsulated fentanyl administered by pulmonary inhalation for the treatment of severe and moderate acute pain, including cancer pain. In addition, its other product candidates include TGFa and HER-1, the anti-cancer vaccines.

Three Rivers Pharmaceuticals is looking to flow powerful drugs into the vast sea of customer affordability. The drug maker develops, manufactures, and distributes specialty pharmaceutical products for the treatment of chronic conditions, particularly viral and fungal ailments. Three Rivers Pharmaceuticals makes and markets two hepatitis C treatments in the US market: Ribasphere (a generic version of the antiviral Ribavirin) and Infergen (a branded antiviral therapy). The company also sells an injectable antifungal medication, Amphotec (also known as Amphocil), in more than 40 countries.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders, and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates.

FAES was founded in 1933. Faes Farma SA is a Spanish company primarily engaged in the research, manufacture and commercialization of pharmaceutical products, such as prescription drugs, over-the-counter medicines and skin-care treatments, as well as raw materials used in the pharmaceutical industry. The Company’s facilities include one research and development center and three manufacturing plants, which are located in the cities of Leioa, Lisbon and Madrid. The Company is a parent of Grupo Faes, a group which comprises Laboratorios Vitoria SA, Laboratorios Veris SA, Iquinosa Farma SA, Lazlo International SA, Hispana Dos SA SICAV, Ingaso Farm SLU, Biotecnet I MAS D SA, Esfion SA, Olve Farmaceutica Lda, Veris Farmaceutica Lda, Vitalion Lda and Farmalavi Lda. Through its subsidiaries, the Company operates mainly in Spain and Portugal. It also has presence in approximately 50 countries in Europe, America, Africa and Asia.

Pacific Biosciences, Inc. company was founded in 2004 and is based in Menlo Park, California. Pacific Biosciences, Inc. operates as a biotechnology company in North America. The company develops a transformative single-molecule (SMRT) DNA sequencing platform, which enables the observation of natural DNA synthesis by a DNA polymerase as it occurs; simplifies the resequencing of complex genomes; and the characterization of structural variation, including insertions, deletions, and rearrangements. Its products include SMRT chip, which enables the observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a signal-to-noise ratio; and Phospholinked nucleotides that produce a natural DNA strand through DNA synthesis. Its product applications include de novo sequencing and resequencing. Pacific Biosciences, Inc. was formerly known as Nanofluidics, Inc.

BMP Sunstone Corporation, formerly Beijing Med-Pharm Corporation, is a specialty pharmaceutical company with over-the-counter (OTC) manufacturing, marketing and distribution based in China. Through its subsidiary, Sunstone (Tangshan) Pharmaceutical Co., Ltd. (Sunstone) it manufactures, markets and distributes OTC products in China. Through Beijing Medpharm Co. Ltd. (BMP China), Beijing Wanwei Pharmaceutical Co., Ltd., (Wanwei), and Shanghai Rongheng Pharmaceutical Company (Rongheng), it offers to foreign and domestic pharmaceutical manufacturers in China, services focused primarily on marketing and promotional services and distribution services. It operates in three segments: branded OTC segment, which includes the operations of Sunstone, Pharmaceutical Distribution segment, which includes the operations of Wanwei and Rongheng and Licensed Products segment, which includes the operations of BMP China. On July 4, 2008, it completed the acquisition of 63.3% interest in Rongheng.

EraGen Biosciences, Inc. company is developing nucleic databases and other tools to help drug and diagnostics developers better use genomic information to streamline their R&D processes. Molecular clinical diagnostics, bioterrorism threat detection, and pesonalized medicine are other markets the company is pursuing. EraGen Biosciences has teamed with Luminex to distribute in vitro clinical diagnostics equipment that uses technology from both companies. Bayer HealthCare has licensed the company's MultiCode-PLx test for detecting cystic fibrosis.

Medical Nutrition USA, Inc. engages in the development and distribution of nutritional and health products in the United States. Its products primarily include the Pro-Stat line of enzyme-hydrolyzed liquid protein for the treatment of unintended weight loss, protein energy malnutrition, and pressure ulcers; UTI-Stat, a urinary tract cleansing complex used to reduce the incidence of urinary tract infection and promote urinary tract health; and Fiber-Stat, a liquid soluble fiber with FOS used to maintain bowel regularity and probiotic intestinal health. Medical Nutrition company's customers include long-term care facilities, hospitals, dialysis clinics, physicians, dispensing medical clinics, nursing homes, and network marketing companies. Medical Nutrition USA sells its branded products directly to distributors, who resell the products to end users, as well as sells through health food stores under private label or licensing agreements. Medical Nutrition USA, Inc. is based in Englewood, New Jersey.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.